Analyst Ratings for Acadia Pharmaceuticals (ACAD)
ACAD Rating Summary
ACAD Price Target Summary
- Highest: $37.00 (Cantor Fitzgerald)
- Lowest: $20.00 (Stifel)
- Average: $29.67
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$29.67 (+73.4%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 39%
Avg. $ Target:
$29.67 (+73.4%)
* Over Last 12-Mos
Rating Score: 4.3 / 10
Percentile Rank: 39%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/16/2022 | Canaccord Genuity | Sumant Kulkami | Upgrade | Buy (Hold) |
31.00 (30.00) |
22.27 (17.11) |
-23.17% | Details |
| 2/9/2022 | H.C. Wainwright | Andrew S. Fein | Upgrade | Buy (N/A) |
36.00 (18.00) |
25.13 (17.11) |
-31.91% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
ACAD Ratings News
- Acadia Pharmaceuticals (ACAD) Earnings Preview - Oppenheimer
- Acadia Pharmaceuticals (ACAD) Earnings Preview: Mizuho Sees Q1 Nuplazid Sales of $120M, Hopes to Hear Updates on Review of Nuplazid for Alzheimer's, Reiterates Neutral Rating
- Acadia Pharmaceuticals (ACAD) PT Lowered to $27 at Mizuho Securities on ACP-044 Failure, Expects "Modest Weakness" in Shares
- See More
